Pharmacyclics Board of Directors
Robert W. Duggan - CEO & Chairman of the Board of Directors
Chief Executive Officer and Chairman of the Board of Directors of Pharmacyclics. Mr. Duggan has been a member of the Board of Directors since September 2007 and was voted in as Chairman in September of 2008 after the resignation of its former Chairman. Since that time, Mr. Duggan has not assumed any pay or has received any options for his services to the company. In December 2008 and in March 2009, at a time the company needed operating funds, Mr. Duggan provided a loan to the company totaling $6.4M. With the receipts of funds raised through a rights offering, Mr. Duggan’s loan was paid back and he used the funds to participate at the same conditions as all other shareholders in the rights offering at his pro rata share. Alongside other biotech investors, Mr. Duggan invested since 2008 in three capital raises which were priced at market closes without any discounts. He purchased all his shares in Pharmacyclics outright and currently owns directly and indirectly approximately 20% of the outstanding shares.
Mr. Duggan has also served as Chairman of the Board of Directors of Computer Motion, Inc., a computerized surgical systems company, from 1990 to 2003 and Chief Executive Officer from 1997. Computer Motion was acquired by Intuitive Surgical, Inc. in 2003. At that time Mr. Duggan became a Board Member of Intuitive Surgical, Inc. and served on its board until March 2011. Mr. Duggan has been an entrepreneur and industrialist for more than 30 years. He has participated as a CEO of, a director of, investor in and advisor to numerous small and large businesses in the medical equipment, computer local and wide area network, PC hardware and software distribution, digital encryption, consumer retail goods and outdoor media communication industry. Mr. Duggan has also assisted in corporate planning, capital formation and management for his various investments. In 1985 he received a Congressman’s Medal of Merit from Congressman Ron Paul and in 2000 he was named a Knight of the Legion of Honor by President Jacques Chirac. Mr. Duggan is a member of the University of California at Santa Barbara Foundation Board of Trustees.
Robert Booth, Ph.D.
Dr. Booth is currently the Chief Executive Officer of Virobay, Inc., a drug discovery and development company. Dr. Booth was also the Executive Chairman of Virobay, Inc. from 2006 to 2010 and served concurrently as an Operating Partner and Senior Advisor at TPG Biotech, a venture capital company. From 2006 to 2007, Dr. Booth served as the acting Chief Scientific Officer of Galleon Pharmaceuticals, a company which is developing new therapeutics for diseases of the respiratory system. From 2002 to 2006, Dr. Booth was the Chief Scientific Officer at Celera Genomics, where he was responsible for leading all discovery and development activities. The therapeutic areas pursued by Celera included oncology, autoimmunity, respiratory diseases and thrombosis. Dr. Booth was Senior Vice President at Roche Bioscience from 1989 to 2002, and was responsible for research and early development activities in the therapeutic areas of inflammation, autoimmunity, respiratory diseases, transplantation, bone diseases and viral diseases. Dr. Booth was a member of the Global Research Management Team and a member of the Business Development Committee, which oversaw licensing opportunities for Roche. During his time at Roche, Dr. Booth managed R&D organizations in both the US and Europe. The Biology team for which Dr. Booth was responsible in the U.K. discovered and contributed to the development of saquinavir, the first HIV protease inhibitor to be launched. This achievement was recognized by the winning of the Prix Galien for Roche. Dr. Booth is currently a member of the Scientific Advisory Board of ShangPharma, a large, privately held CRO in China. Dr. Booth received his Ph.D. and B.Sc. from the University of London in the field of biochemistry. (1*)(3)
Eric Halvorson, J.D.
Mr. Halvorson has been Of Counsel to the law firm of Stowell, Zeilenga, Ruth, Vaughn & Treiger, LLP since 2010. Mr. Halvorson was President and Chief Operating Officer of Salem Communications Corporation from 2007 to 2008. He was Executive Vice President and Chief Operating Officer of Salem Communications Corporation from 1995 to 2000. Prior to becoming Chief Operating Officer, he was the company’s Vice President and General Counsel for ten years. Mr. Halvorson was a member of the Board of Directors of Salem Communications Corporation from 1988 to 2008. He has been a member of the Board of Directors of Intuitive Surgical, Inc. since 2003. From 2000-2003, 2005-2007 and 2009-2011, Mr. Halvorson was Executive in Residence at Pepperdine University and Adjunct Professor of Law at Pepperdine Law School. From 2003-2005, Mr. Halvorson served as President and Chief Executive Officer of The Thomas Kinkade Company. He was a partner at Godfrey & Kahn, a law firm based in Milwaukee, Wisconsin, from 1976-1985. Mr. Halvorson holds a B.S. in Accounting from Bob Jones University and a J.D. from Duke University School of Law.(1)(2*)
Mr. Clark has been a member of the law firm Wilson Sonsini Goodrich & Rosati, PC, since 1993, and currently serves as a member of its Board of Directors. His practice has focused on strategic transactions in the biopharmaceutical industry for over 25 years, and has included several of the largest partnering transactions in the industry over that period. He holds a B.A. degree from Vanderbilt University and a law degree from the University of Texas at Austin.
Minesh Mehta, M.D.
Dr. Mehta is an internationally recognized expert in human clinical drug and drug-radiation trial strategy, design and execution and has managed national and international trials of all sizes. He is a professor in the Department of Radiation Oncology at Northwestern University, Chicago. Dr. Mehta currently chairs the Brain Tumor Committee in the Radiation Therapy Oncology Group. He has authored over 80 clinical protocols, over 600 clinical publications to his credit. Dr. Mehta obtained his medical degree at the University of Zambia, and completed his residency in radiation oncology at the University of Wisconsin, Madison. (4)
David Smith, Ph.D
Dr. Smith is Professor and Assistant Director of Biostatistics at City of Hope cancer research hospital in Los Angeles, where he has designed and analyzed over 50 solid tumor and hematology protocols at all levels of development, from pre-clinical and genomic studies to Phase II/III trials. Prior to his tenure at City of Hope, he served as a biostatistical reviewer for the Division of Oncology Drug Products at the U.S. Food and Drug Administration for three years, during which time he reviewed more than 40 chemotherapy INDs and NDAs. Dr. Smith has been a co-investigator on grants from the National Cancer Institute, National Institutes of Health, the American Cancer Society, the Susan G. Komen Breast Cancer Foundation and the Leukemia & Lymphoma Society. He is an author and coauthor of over 40 papers in peer-reviewed biostatistics, oncology, surgery, radiation, and immunology journals. Dr. Smith holds a B.A. in Mathematics and a Ph.D in Statistics. (1)(3)(4*)
Richard van den Broek
Richard van den Broek joined the Company as a director in March 2008. Since 2004, Mr. van den Broek has been Managing Partner of HSMR Advisors, LLC, an investment fund focused on the biotechnology industry. From 2000 through 2003 he was a Partner at Cooper Hill Partners, LLC, an investment fund focused on the healthcare sector. Prior to that Mr. van den Broek had a ten year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist. Mr. van den Broek is a graduate of Harvard University and is a Chartered Financial Analyst. (1)(2)
||Member of the Nominating and Corporate Governance Committee
||Member of the Audit Committee
||Member of the Compensation Committee
||Member of the Clinical Review Committee
Back to top